CDK4 and melanoma: Regarding tumor suppressors, CDKN2A, the CDK4/6 inhibitor, which is deleted or mutated in 40% of melanomas, and the PI3K/AKT pathway inhibitor, which exhibits characteristic loss of function in 20–30% of melanomas, were considered.